Phenotips Raises $2.5M in First Round of Financing
Our startup company, Phenotips (formerly Gene42), announced in September, 2021, that it raised C$2.5M in its first round of financing. TIAP was an early investor and most recently, in this…
Bristol Myers Squibb Enters Agreement to Acquire Forbius
TIAP portfolio company Forbius announced on August 24, 2020 that they have entered into an acquisition deal with Bristol Myers Squibb. BMS is adding lead TGF-beta asset to its portfolio…
LAB150 launches new immuno-oncology project from Sunnybrook Research Institute
Toronto, Ontario, June 04, 2020 (GLOBE NEWSWIRE) -- Toronto Innovation Acceleration Partners (TIAP) announced today the launch of a new LAB150 project aimed at developing a novel therapeutic agent for…
Zucara Therapeutics Announces US$21M Series A Financing
– Proceeds to Fund Development of ZT-01 Through Phase 2 Clinical Trials – – Series A Financing led by the Perceptive Xontogeny Venture Fund – TORONTO, March 31, 2020 (GLOBE…
Notch Therapeutics, a new company in the field of gene-modified T cell therapy
Toronto, ON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Notch Therapeutics, a company in the emerging field of gene-modified T cell therapy, has been created to commercialize a revolutionary technology that…
Zealand Pharma Acquires Encycle Therapeutics
Our portfolio company, Encycle Therapeutics, has been acquired by Danish Zealand Pharma. The transaction strengthens the leadership of Zealand Pharma (NASDAQ: ZEAL) in peptide therapeutics and in targeting gastrointestinal diseases with…
AmacaThera, a TIAP Portfolio Company, Closes Seed Financing Round
TORONTO, Oct. 3, 2019 /PRNewswire/ -- AmacaThera Inc. (www.amacathera.ca) is pleased to announce the closing of its US $3.6M seed financing round. A first close of the round was led by Sprout…
LAB150 adds two projects: Cystic Fibrosis and Respiratory Syncytial Virus
Toronto, ON, Feb. 27, 2019 (GLOBE NEWSWIRE) -- MaRS Innovation announced today the concurrent launch of two new LAB150 projects. These projects build on breakthroughs in disease-focused scientific research by…
Fibrocor Therapeutics enters deal with Galapagos NV
Toronto, ON, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Fibrocor Therapeutics, a privately held Canadian company, and Galapagos NV, a Belgo-Dutch pharmaceutical research company, have announced the formation of a partnership…
$800,000 MaRS Innovation–Pfizer Translational Research Fund
KIRKLAND, Quebec and TORONTO, April 09, 2018 (GLOBE NEWSWIRE) -- Pfizer Canada is proud to announce an $800,000 contribution to MaRS Innovation to support the vision and mission of MaRS…